

ELECTRONICALLY  
FILED  
Dec 27 2023  
U.S. DISTRICT COURT  
Northern District of WV

**IN THE UNITED STATES DISTRICT COURT  
FOR THE NORTHERN DISTRICT OF WEST VIRGINIA  
CLARKSBURG DIVISION**

REGENERON PHARMACEUTICALS, INC.

Plaintiff,

v.

SAMSUNG BIOEPIS CO., LTD.,

Defendant.

CASE NO.: **1:23-CV-106 (Kleeh)**

JURY TRIAL DEMANDED

**COMPLAINT**

Plaintiff Regeneron Pharmaceuticals, Inc. (“Regeneron” or “Plaintiff”), invented, developed, and sells EYLEA<sup>®</sup>, the market-leading treatment for several serious eye diseases. Defendant Samsung Bioepis Co., Ltd. (“Bioepis” or “Defendant”) is seeking

[REDACTED]



### NATURE OF THE CASE

1. Regeneron is a leading science-based American biotechnology company. With a focus on patient access and fair drug pricing, Regeneron is dedicated to innovation, improving human health, and tackling the most urgent medical issues facing the Nation. Founded and led for over 30 years by physician-scientists, Regeneron has developed life-transforming medicines for people with serious diseases, including cancer, atopic dermatitis, asthma, eye diseases, cardiovascular and metabolic diseases, Ebola, and COVID-19, which have been used across the country. Regeneron’s cutting-edge scientific advances are supported, in large part, by its ophthalmic product, EYLEA<sup>®</sup>, which FDA approved in 2011.

2. EYLEA<sup>®</sup> has been administered millions of times to treat certain ophthalmic disorders that, if left untreated, can lead to permanent blindness. Its active ingredient is a genetically engineered fusion protein called aflibercept. It works by blocking the overproduction of a naturally occurring protein in the eye that can cause the formation of new blood vessels, leading to vision loss. Based on extensive clinical testing by Regeneron, FDA approved EYLEA<sup>®</sup> in 2011 to treat an ophthalmic disorder called neovascular (wet) age-related macular degeneration (“wAMD”) and in 2014 to treat diabetic macular edema (“DME”). As a result of Regeneron’s additional clinical testing, EYLEA<sup>®</sup> is now also approved for use in treating other serious disorders

---

<sup>1</sup> As explained in its forthcoming memorandum in support of its motion to seal, Regeneron is bound by the provisions of 42 U.S.C. § 262(l)(1), which dictate that Bioepis determine, “in its sole discretion,” what information constitutes Bioepis confidential information, that no such “confidential information shall be included in any publicly-available complaint or other pleading,” and any violation of paragraph 1 could result in “irreparable harm for which there is no adequate legal remedy” and for which “the court shall consider immediate injunctive relief to be an appropriate and necessary remedy.” Therefore, Regeneron initiates this case by filing a public version of this Complaint with redactions to any information that Bioepis has represented is Bioepis confidential information.

of the eye: macular edema following retinal vein occlusion and diabetic retinopathy. Most recently, FDA granted approval for EYLEA<sup>®</sup> to treat retinopathy of prematurity in preterm infants, which is the leading cause of childhood blindness worldwide. In addition to benefitting the many patients it has been used to treat, EYLEA<sup>®</sup> is also a critical source of research and development funding for Regeneron to develop other life-transforming medicines.

3. [REDACTED]

[REDACTED] Enacted in 2010 as part of the Affordable Care Act, the BPCIA provides for an abbreviated regulatory approval pathway for biosimilars by letting applicants rely on the extensive clinical testing previously conducted, at great expense, by the innovator company that developed the medicine the applicant wants to copy. *See Sandoz Inc. v. Amgen Inc.*, 582 U.S. 1 (2017).

4. [REDACTED]

[REDACTED]

5. [REDACTED]

[REDACTED]

[REDACTED] This action is brought in addition to a related pending action before this Court. *See Regeneron Pharmaceuticals, Inc. v.*

*Samsung Bioepis, Co., Ltd.*, No. 23-CV-00094-TSK (N.D.W. Va.).

**THE PARTIES, JURISDICTION, AND VENUE**

6. Plaintiff Regeneron is a corporation organized and existing under the laws of the State of New York with its principal place of business located at 777 Old Saw Mill River Road, Tarrytown, New York 10591. Regeneron is dedicated to discovering, developing, and commercializing medicines to treat patients with debilitating and life-threatening diseases. Regeneron owns each of the patents asserted in this Complaint (collectively, the “asserted patents” or the “patents in suit”):

<b>Patent</b>	<b>First Named Inventor</b>
9,222,106	Gang Chen
9,254,338	George D. Yancopoulos
9,315,281	Tikiri Jean Dissanayake
9,562,238	Gang Chen
9,816,110	Ying Shen
10,130,681	George D. Yancopoulos
10,415,055	Gang Chen
10,464,992	Eric Furfine
10,669,594	Serge Monpoeho
10,828,345	George D. Yancopoulos
10,888,601	George D. Yancopoulos
10,905,786	Philip Stephen Shodder
10,918,754	Philip Stephen Shodder
10,927,342	Amy S. Johnson
11,053,280	Andrew Tustian
11,066,458	Eric Furfine
11,084,865	Eric Furfine
11,104,715	Shawn Lawrence
11,174,283	Andrew Tustian
11,253,572	George D. Yancopoulos
11,299,532	Andrew Tustian
11,306,135	Shunhai Wang
11,312,936	Amy S. Johnson
11,332,771	Shadia Abike Oshodi
11,472,861	Shawn Lawrence
11,485,770	Shunhai Wang
11,535,663	Shawn Lawrence
11,542,317	Shunhai Wang

11,548,932	Shunhai Wang
11,555,176	Wei Xue
11,559,564	George D. Yancopoulos
11,707,506	George D. Yancopoulos
11,732,024	Eric Furfine
11,753,459	Shunhai Wang
11,769,597	Lorah Perlee
11,788,102	Ying Shen
10,182,969*	Rachel Paige Arnott
11,103,552†	Kenneth S. Graham
11,160,918*	Andrew Cook
11,433,186*	Sibgat Ulla
11,439,758*	Trevor Langley
11,459,374*	Andrew Tustian
11,478,588*	Bryan Grygus
11,505,593*	Shunhai Wang
11,577,025*	Daniel B. Dix
11,793,926*	Andrew Cook
USD 858,754*	Bryan Grygus
USD 906,102*	Andrew Cook
USD 934,069*	Andrew Cook
USD 961,376*	Andrew Cook
USD 961,377*	Andrew Cook

7. On information and belief, Bioepis is a company organized and existing under the laws of the Republic of Korea with its principal place of business located at 76, Songdogyoyuk-ro, Yeonsu-gu, Incheon, Republic of Korea. Bioepis is a biopharmaceutical company that specializes in research and development of biosimilars and biopharmaceuticals.

8. On information and belief, Bioepis, directly or indirectly, manufactures its drug products abroad. On information and belief, Bioepis directly, or via its subsidiaries, affiliates, or other agents, develops, distributes, or sells within the United States or imports into the United States Bioepis's drug products, including SB15, under the general direction and control of Bioepis. Non-limiting examples are provided below.

9. Bioepis is the holder of aBLA No. 761054 for RENFLEXIS, an approved biosimilar of Remicade. On information and belief, Bioepis manufactures and imports

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.